Literature DB >> 23426429

A comparison of the theoretical relationship between HDL size and the ratio of HDL cholesterol to apolipoprotein A-I with experimental results from the Women's Health Study.

Norman A Mazer1, Franco Giulianini, Nina P Paynter, Paul Jordan, Samia Mora.   

Abstract

BACKGROUND: HDL size and composition vary among individuals and may be associated with cardiovascular disease and diabetes. We investigated the theoretical relationship between HDL size and composition using an updated version of the spherical model of lipoprotein structure proposed by Shen et al. (Proc Natl Acad Sci U S A 1977;74:837-41.) and compared its predictions with experimental data from the Women's Health Study (WHS).
METHODS: The Shen model was updated to predict the relationship between HDL diameter and the ratio of HDL-cholesterol (HDL-C) to apolipoprotein A-I (ApoA-I) plasma concentrations (HDL-C/ApoA-I ratio). In the WHS (n = 26 772), nuclear magnetic resonance spectroscopy (NMR) was used to measure the mean HDL diameter (d(mean,NMR)) and particle concentration (HDL-P); HDL-C and ApoA-I (mg/dL) were measured by standardized assays.
RESULTS: The updated Shen model predicts a quasilinear increase of HDL diameter with the HDL-C/ApoA-I ratio, consistent with the d(mean,NMR) values from WHS, which ranged between 8.0 and 10.8 nm and correlated positively with the HDL-C/ApoA-I ratio (r = 0.608, P < 2.2 × 10(-16)). The WHS data were further described by a linear regression equation: d(WHS) = 4.66 nm + 12.31(HDL-C/Apo-I), where d(WHS) is expressed in nanometers. The validity of this equation for estimating HDL size was assessed with data from cholesteryl ester transfer protein deficiency and pharmacologic inhibition. We also illustrate how HDL-P can be estimated from the HDL size and ApoA-I concentration.
CONCLUSIONS: This study provides a large-scale experimental examination of the updated Shen model. The results offer new insights into HDL structure, composition and remodeling and suggest that the HDL-C/ApoA-I ratio might be a readily available biomarker for estimating HDL size and HDL-P.
© 2013 American Association for Clinical Chemistry.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23426429      PMCID: PMC3669243          DOI: 10.1373/clinchem.2012.196949

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  35 in total

1.  Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib.

Authors:  Ronald M Krauss; Kathleen Wojnooski; Joseph Orr; J Casey Geaney; Cathy Anne Pinto; Yang Liu; John A Wagner; Julie Mabalot Luk; Amy O Johnson-Levonas; Matt S Anderson; Hayes M Dansky
Journal:  J Lipid Res       Date:  2011-12-17       Impact factor: 5.922

2.  HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events.

Authors:  Robert S Rosenson; H Bryan Brewer; M John Chapman; Sergio Fazio; M Mahmood Hussain; Anatol Kontush; Ronald M Krauss; James D Otvos; Alan T Remaley; Ernst J Schaefer
Journal:  Clin Chem       Date:  2011-01-25       Impact factor: 8.327

3.  Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study.

Authors:  Christie M Ballantyne; Michael Miller; Eric J Niesor; Tracy Burgess; David Kallend; Evan A Stein
Journal:  Am Heart J       Date:  2012-03       Impact factor: 4.749

4.  High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis).

Authors:  Rachel H Mackey; Philip Greenland; David C Goff; Donald Lloyd-Jones; Christopher T Sibley; Samia Mora
Journal:  J Am Coll Cardiol       Date:  2012-07-11       Impact factor: 24.094

5.  Analysis of the relationship between triglyceridemia and HDL-phospholipid concentrations: consequences on the efflux capacity of serum in the Fu5AH system.

Authors:  N Fournier; V Atger; A Cogny; B Vedie; P Giral; A Simon; N Moatti; J L Paul
Journal:  Atherosclerosis       Date:  2001-08       Impact factor: 5.162

6.  Lipoprotein subclass abnormalities and incident hypertension in initially healthy women.

Authors:  Nina P Paynter; Howard D Sesso; David Conen; James D Otvos; Samia Mora
Journal:  Clin Chem       Date:  2011-06-23       Impact factor: 8.327

7.  Safety of anacetrapib in patients with or at high risk for coronary heart disease.

Authors:  Christopher P Cannon; Sukrut Shah; Hayes M Dansky; Michael Davidson; Eliot A Brinton; Antonio M Gotto; Michael Stepanavage; Sherry Xueyu Liu; Patrice Gibbons; Tanya B Ashraf; Jennifer Zafarino; Yale Mitchel; Philip Barter
Journal:  N Engl J Med       Date:  2010-11-17       Impact factor: 91.245

Review 8.  Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.

Authors:  Eric J Niesor
Journal:  Curr Opin Lipidol       Date:  2011-08       Impact factor: 4.776

Review 9.  Clinical review: The evolving role of HDL in the treatment of high-risk patients with cardiovascular disease.

Authors:  H Bryan Brewer
Journal:  J Clin Endocrinol Metab       Date:  2011-03-09       Impact factor: 5.958

10.  Hepatic lipase activity influences high density lipoprotein subclass distribution in normotriglyceridemic men. Genetic and pharmacological evidence.

Authors:  S M Grundy; G L Vega; J D Otvos; D L Rainwater; J C Cohen
Journal:  J Lipid Res       Date:  1999-02       Impact factor: 5.922

View more
  19 in total

1.  LDL and HDL transfer rates across peripheral microvascular endothelium agree with those predicted for passive ultrafiltration in humans.

Authors:  C Charles Michel; M Nazeem Nanjee; Waldemar L Olszewski; Norman E Miller
Journal:  J Lipid Res       Date:  2014-11-14       Impact factor: 5.922

2.  Liposcale: a novel advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy.

Authors:  Roger Mallol; Núria Amigó; Miguel A Rodríguez; Mercedes Heras; Maria Vinaixa; Núria Plana; Edmond Rock; Josep Ribalta; Oscar Yanes; Lluís Masana; Xavier Correig
Journal:  J Lipid Res       Date:  2015-01-07       Impact factor: 5.922

3.  Participation of white adipose tissue dysfunction on circulating HDL cholesterol and HDL particle size in apparently healthy humans.

Authors:  Juan G Juárez-Rojas; Ivan Torre-Villalvazo; Aida X Medina-Urrutia; Juan Reyes-Barrera; Víctor H Sainz-Escárrega; Carlos Posadas-Romero; Alejandro Macías-Cruz; Esteban Jorge-Galarza
Journal:  Int J Obes (Lond)       Date:  2019-12-02       Impact factor: 5.095

4.  The ratio of high-density lipoprotein cholesterol to apolipoprotein A-I predicts myocardial injury following elective percutaneous coronary intervention.

Authors:  Xiao-Lin Li; Jian-Jun Li; Yuan-Lin Guo; Cheng-Gang Zhu; Ping Qing; Na-Qiong Wu; Bo Xu; Run-Lin Gao
Journal:  Clin Cardiol       Date:  2014-08-11       Impact factor: 2.882

5.  Marginal Zinc Deficiency Alters Essential Fatty Acid Metabolism in Healthy Men.

Authors:  Jung H Suh; Sarah J Zyba; Mark Shigenaga; Christine M McDonald; Janet C King
Journal:  J Nutr       Date:  2022-03-03       Impact factor: 4.687

6.  Impact of estimated HDL particle size via the ratio of HDL-C and apoprotein A-I on short-term prognosis of diabetic patients with stable coronary artery disease.

Authors:  Li-Feng Hong; Bo Yang; Song-Hui Luo; Jian-Jun Li
Journal:  J Geriatr Cardiol       Date:  2014-09       Impact factor: 3.327

7.  Association between High-Density Lipoprotein Cholesterol to Apolipoprotein A-I Ratio and Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study.

Authors:  Hangkai Huang; Jinghua Wang; Lei Xu; Min Miao; Chengfu Xu
Journal:  Int J Endocrinol       Date:  2021-06-04       Impact factor: 3.257

8.  The rs12617336 and rs17574 Dipeptidyl Peptidase-4 Polymorphisms Are Associated With Hypoalphalipoproteinemia and Dipeptidyl Peptidase-4 Serum Levels: A Case-Control Study of the Genetics of Atherosclerotic Disease (GEA) Cohort.

Authors:  Gilberto Vargas-Alarcón; María Del Carmen González-Salazar; Christian Vázquez-Vázquez; Adrián Hernández-Díaz Couder; Fausto Sánchez-Muñoz; Juan Reyes-Barrera; Sergio A Criales-Vera; Marco Sánchez-Guerra; Citlalli Osorio-Yáñez; Rosalinda Posadas-Sánchez
Journal:  Front Genet       Date:  2021-06-11       Impact factor: 4.599

9.  Analysis of "On/Off" Kinetics of a CETP Inhibitor Using a Mechanistic Model of Lipoprotein Metabolism and Kinetics.

Authors:  J Lu; Y Cleary; C Maugeais; C I Kiu Weber; N A Mazer
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-04-20

10.  An in-silico model of lipoprotein metabolism and kinetics for the evaluation of targets and biomarkers in the reverse cholesterol transport pathway.

Authors:  James Lu; Katrin Hübner; M Nazeem Nanjee; Eliot A Brinton; Norman A Mazer
Journal:  PLoS Comput Biol       Date:  2014-03-13       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.